sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the clinical efficacy of treatment regimen in terms of
objective response rate (ORR). The secondary objectives is to determine the clinical efficacy
of the study treatment in terms of progression free survival (PFS) and overall survival (OS).
Additionally, to characterize the safety and toxicity profile of the study treatment as
measured by the adverse event rates.